At what enterprise value was MEDICAL-SURGICAL SOLUTIONS acquired in 2026?

During the acquisition of MEDICAL-SURGICAL SOLUTIONS by APOLLO GLOBAL MANAGEMENT in 2026, the transaction's Enterprise Value is estimated to be in the range of 3b - 100b USD.

What was the EV/EBITDA of MEDICAL-SURGICAL SOLUTIONS when it was acquired by APOLLO GLOBAL MANAGEMENT?

The estimated EV/EBITDA multiple for MEDICAL-SURGICAL SOLUTIONS is in the range of 10x - 18x.

What was the revenue of MEDICAL-SURGICAL SOLUTIONS at the time of the deal?

The revenue of MEDICAL-SURGICAL SOLUTIONS at the time of the deal is estimated to be in the range of 5b - 100b USD.

What was the EBITDA of MEDICAL-SURGICAL SOLUTIONS during the acquisition?

MEDICAL-SURGICAL SOLUTIONS's EBITDA is estimated to be in the range of 750M - 1.3b USD.

How is the data for the MEDICAL-SURGICAL SOLUTIONS acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the MEDICAL-SURGICAL SOLUTIONS deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.mckesson.com/about-us/newsroom/press-releases/2026/mckesson-signs-agreement-with-apollo-funds-for-strategic-minority-interest-in-medical-surgical-solutions/

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.5x.

← DATABASE

Home Database Healthcare & PharmaMEDICAL-SURGICAL SOLUTIONS

04/2026

MEDICAL-SURGICAL SOLUTIONS acquired by APOLLO GLOBAL MANAGEMENT

UNITED STATES Healthcare Services / Hospital Logistics EV 3b - 100b USD

Context

McKesson Corporation has finalized a definitive agreement to sell a minority ownership interest (13%) in its Medical-Surgical Solutions (MMS) business to funds managed by affiliates of Apollo. The strategic rationale for this transaction centers on a "separation-validation" play, merging the target's industry-leading technical operational depth in healthcare distribution with the acquirer's extensive expertise in supporting complex corporate carve-outs. This structural alignment provides the organization with the strategic and financial flexibility required to pursue its definitive separation strategy in preparation for a planned initial public offering. This operation allows the group to execute a definitive structural transition toward operating as a standalone company while maintaining a well-capitalized balance sheet. By incorporating the sponsor's strategic discipline and experience in public market transactions, the organization is now positioned to optimize its governance and operational platforms.

MEDICAL-SURGICAL SOLUTIONS, which reported an EBITDA margin of in 2025, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (14.5x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Medical-Surgical Solutions, MSS, operates as a comprehensive distributor of medical-surgical supplies, offering a specialized portfolio of over 300,000 products including high-precision surgical instruments, exam room diagnostic equipment, and advanced wound care solutions. Its business model integrates the distribution of consumables (such as personal protective equipment (PPE), incontinence products, and clinical laboratory supplies) with sophisticated technical services. These services encompass proprietary inventory management software, supply chain analytics, and clinical consulting designed to optimize the operational efficiency of non-acute facilities. Strategically, the firm focuses on the deployment of point-of-care testing technologies and pharmaceutical distribution tailored for ambulatory surgery centers, physician offices, and home healthcare environments. By providing both the physical hardware and the digital data-driven infrastructure for procurement, the entity facilitates the structural efficiency of localized clinical care.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (USD)

Year

Rev

EBITDA

EBIT

2025

2024

Similar deals in Healthcare Services

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
09/2026	CVC	Unitex Textile Services	UNITED STATES	Sterilization & Hygiene
03/2026	RADNET	GLEAMER	FRANCE	Health Tech
03/2026	THERMO FISHER SCIENTIFIC	CLARIO HOLDINGS	UNITED STATES	CRO / Clinical Trials
01/2026	PERMIRA	CARNE GROUP	IRELAND	Healthcare Services
01/2026	TPG	OPTUM UK	UNITED KINGDOM	Health Tech
01/2026	SAGARD	QUIPMENT	FRANCE	Healthcare Services
01/2026	ANTIN INFRASTRUCTURE	EMSERE	NETHERLANDS	CRO / Clinical Trials
12/2025	PHARMA EQUITY GROUP	OTIOM	DENMARK	Health Tech
11/2025	ASKER HEALTHCARE GROUP	FINMED GROUP	FRANCE	Hospital Logistics
11/2025	EURAZEO	EXCELYA	FRANCE	CRO / Clinical Trials

REFERENCES

Valuation range: EV 3b - 100b USD

Revenue range: 5b - 100b USD

EBITDA range: 750M - 1.3b USD

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of MEDICAL-SURGICAL SOLUTIONS by APOLLO GLOBAL MANAGEMENT are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: apollo global management